Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CENTREXION THERAPEUTICS CORPORATION

(A2N8XT)
Schlusskurs Nasdaq  - 
- USD   -.--%
02.02.CENTREXION THERAPEUTICS CORPORATION : Von HC Wainwright zum Kauf angehoben
MM
24.01.CENTREXION THERAPEUTICS CORPORATION : erhält Kaufen-Rating von ThinkEquity
MM
2021Aktien des Gesundheitswesens bleiben im späten Handel im Plus
MT
ÜbersichtKurseNewsUnternehmenFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über CENTREXION THERAPEUTICS CORPORATION
11.08.Centrexion Therapeutics Corporation announced that it has received $29.14 million in fu..
08.06.Centrexion Therapeutics Corporation announced that it has received $16.475 million in f..
24.05.Centrexion Therapeutics Corporation announced that it expects to receive $16.475 millio..
11.05.CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition ..
11.05.Earnings Flash (CNTX) CONTEXT THERAPEUTICS Posts Q1 Loss $-0.22
11.04.Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Pr..
06.04.Context Therapeutics® to Participate in Two April 2022 Investor Conferences
23.03.CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition ..
23.03.Context Therapeutics® Reports Full Year 2021 Operating and Financial Results
10.01.CONTEXT THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
05.01.CONTEXT THERAPEUTICS INC. : Change in Directors or Principal Officers, Other Events, Finan..
05.01.Context Therapeutics® Strengthens Research & Development Team
2021Health Care Stocks Staying On Positive Ground in Late Trade
2021Health Care Stocks Hanging On For Slim Gains
2021Wall Street Sees Upbeat Open, US CPI Rises More Than Expected
2021Top Premarket Gainers
2021Context Therapeutics Says Drug Candidate Decreased Reproduction of Breast Cancer Tumor ..
2021Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 202..
2021Context Therapeutics Closes $31.3 Million Private Placement of Common Shares, Warrants;..
2021CONTEXT THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2021Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement
2021Context Therapeutics Q3 Net Loss Widens
2021Management's discussion and analysis of financial condition and results of ..
2021Earnings Flash (CNTX) CONTEXT THERAPEUTICS Reports Q3 Loss $-4.00
2021Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results
2021Health Care Stocks Trailing Thursday Field Higher
2021SECTOR UPDATE : Health Care
2021Top Midday Decliners
2021Context Therapeutics Expects to Raise $31.3 Million in Private Placement of Common Shar..
2021Context Therapeutics Inc. Announces $31.25 Million Private Placement
2021Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San A..
2021Context Therapeutics Names Jennifer Minai-Azary Chief Financial Officer
2021CONTEXT THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statement..
2021Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial ..
2021CONTEXT THERAPEUTICS INC. : Change in Directors or Principal Officers, Amendments to Artic..
2021CENTREXION THERAPEUTICS : Context Therapeutics Closes $28.8 Million IPO
2021CENTREXION THERAPEUTICS : Context Therapeutics® Announces Closing of Initial Public Offeri..
2021CENTREXION THERAPEUTICS : Context Therapeutics Debuts On Nasdaq
2021CENTREXION THERAPEUTICS : Context Therapeutics Prices IPO of 5 Million Common Shares at $5..
2021Centrexion Therapeutics Corporation announced that it has received $13.5 million in fun..
2021Centrexion Therapeutics Corporation announced that it expects to receive $13.5 million ..
2020Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management ..
2020Centrexion Therapeutics Corporation announced that it has received funding from Lilly V..
2020Centrexion Therapeutics Corporation has withdrawn its IPO.
2019Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lea..
2019Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American Col..
2019Centrexion Corp Reports Earnings Results for the Half Year Ended June 30, 2019
2019Centrexion Therapeutics Corporation Auditor Raises 'Going Concern' Doubt
2019Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3..
2019Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3..
2019CORRECTION - Centrexion Therapeutics
2019Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Presentations..
2019Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Presentations..
2019Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined C..
2019Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined C..
2019Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Agai..
2019Centrexion Therapeutics Corporation to Announce CNTX-4975 Trial Results At the European..
2019Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical ..
2019Eli Lilly and Company Announces Licensing Agreement for Non-Opioid Pain Asset from Cent..
2019Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Soci..
2019Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for..
2019Centrexion Therapeutics Corporation Announces Publication of Phase 2 Efficacy Data on C..
2019Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations..
2018Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 C..
2018Centrexion Therapeutics Corporation Announces Completion of Patient Enrollment in Pivot..
2018Centrexion Therapeutics Corporation has filed an IPO in the amount of $86.25 million.
2018Centrexion Therapeutics Intends To Seek Acquisitions
2018Centrexion Therapeutics Corporation Auditor Raises 'Going Concern' Doubt
2018Centrexion Therapeutics Corporation Appoints Andrew Partridge as Executive Vice Preside..
2018Centrexion Therapeutics Corporation Appoints Dan Mendelson to its Board of Directors
2018Centrexion Therapeutics Corporation Appoints Nick Harvey as Chief Financial Officer
2018Centrexion Therapeutics Appoints Joseph R. Swedish to its Board of Directors
2018Centrexion Therapeutics Corporation to Present CNTX-4975 Clinical Data at the American ..
2018Centrexion Therapeutics Corporation Announces Fast Track Designation Granted by FDA to ..
2018Centrexion Corp announced that it has received $69.57 million in funding from a group o..
2017Centrexion Corp announced that it expects to receive $69.57 million in funding
2017Centrexion Therapeutics to Present Clinical Data from Pipeline of Chronic Pain Treatmen..
2017Centrexion Therapeutics Provides Updates and Advancements for Pipeline of Chronic Pain ..
2017Shawn Tomasello Joins Centrexion Therapeutics as Member of the Board of Directors
2017Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durabl..
2017Centrexion Corp announced that it has received $5.29 million in funding
2017Centrexion Therapeutics Corporation to Present Data on Cntx-4975 At American Pain Socie..
2017Centrexion Corp announced that it expects to receive $5.29 million in funding
2017Centrexion Therapeutics to Present Phase 2b Clinical Trial of CNTX-4975 for Treatment o..
2017Centrexion Corp announced that it has received $16.56 million in funding
2016Centrexion Corp announced that it expects to receive $16.56 million in funding
2016Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 fo..
2016Centrexion Corp announced that it has received $11.16 million in funding
2016Centrexion Corp announced that it expects to receive $11.16 million in funding
2016Centrexion Corp announced that it has received $6.91 million in funding
2016Centrexion Corp announced that it expects to receive $6.91 million in funding
2016Centrexion Corp announced that it has received $10.52 million in funding
2016Centrexion Corp announced that it expects to receive $10.52 million in funding
2013Centrexion Corp completed the acquisition of Vallinex Inc.
2013Centrexion Corp agreed to acquire Vallinex Inc.